Madrigal Pharmaceuticals, Inc.
(NASDAQ: MDGL)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

496.540 -

-3.850 (-0.77%)
Range 492.000 - 506.395   (2.93%)
Open 504.360
Previous Close 500.390
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume 180,944
Value 74,750,154
Remark -
Delayed prices. Updated at 29 Jan 2026 09:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis